Literature DB >> 15156065

Molecular aspects of disease pathogenesis in the transmissible spongiform encephalopathies.

Suzette A Priola1, Ina Vorberg.   

Abstract

The transmissible spongiform encephalopathy (TSE) diseases are a group of rare, fatal, and transmissible neurodegenerative diseases that include kuru and Creutzfeldt-Jakob disease (CJD) in humans, scrapie in sheep, transmissible mink encephalopathy (TME), and chronic wasting disease (CWD) in mule deer and elk. Over the last 20 yr, they have gone from a fascinating but relatively obscure group of diseases to one that is a major agricultural and economic problem as well as a threat to human health. The shift in the relative impact of the TSE diseases began in the late 1970s when the United Kingdom altered the process by which animal carcasses were rendered to provide a protein supplement (i.e., meat and bone meal) to sheep, cattle, and other livestock. Several years later a new disease was recognized in the British cattle population. The pathological and immunohistochemical characteristics of the disease clearly placed it among the TSEs. The new disease was named bovine spongiform encephalopathy (BSE) by the scientific community and "mad cow disease" by the less-than-scientific press. At its peak in the UK, several thousand cattle a year were diagnosed with BSE, and millions of cattle were slaughtered. Introduction of the specified offals ban as well as banning the practice of feeding ruminants to other ruminants has led to a drastic decrease in the number of yearly BSE cases in the UK (less than 500 in 2003), and the epidemic is clearly on the wane. However, BSE has now spread throughout the rest of Europe, as well as to Japan, Russia, Canada, and Israel and thus remains a worldwide problem.A primary concern following the identification of BSE in 1985 was that it might cross species barriers to infect humans. Initially, it was thought that transmission of BSE to humans was unlikely, given that humans appeared to be resistant to scrapie, an animal TSE that had been endemic in British sheep for centuries. However, a few years after BSE was first recognized, a previously unknown form of CJD (variant CJD or vCJD) was identified in young people in Great Britain. The hypothesis that vCJD was the consequence of exposure of humans to BSE has now been supported by several different studies, and over 140 cases of vCJD have been confirmed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15156065     DOI: 10.1385/1-59259-766-1:517

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

1.  DNA polymorphisms of the prion doppel gene region in four different German cattle breeds and cows tested positive for bovine spongiform encephalopathy.

Authors:  N Balbus; A Humeny; K Kashkevich; I Henz; C Fischer; C-M Becker; K Schiebel
Journal:  Mamm Genome       Date:  2005-11-11       Impact factor: 2.957

Review 2.  Prion protein scrapie and the normal cellular prion protein.

Authors:  Caroline J Atkinson; Kai Zhang; Alan L Munn; Adrian Wiegmans; Ming Q Wei
Journal:  Prion       Date:  2016       Impact factor: 3.931

3.  Bovine spongiform encephalopathy infection alters endogenous retrovirus expression in distinct brain regions of cynomolgus macaques (Macaca fascicularis).

Authors:  Alex D Greenwood; Michelle Vincendeau; Ann-Christin Schmädicke; Judith Montag; Wolfgang Seifarth; Dirk Motzkus
Journal:  Mol Neurodegener       Date:  2011-06-23       Impact factor: 14.195

4.  Treatment of Prion Disease with Heterologous Prion Proteins.

Authors:  Pamela J Skinner; Hyeon O Kim; Damani Bryant; Nikilyn J Kinzel; Cavan Reilly; Suzette A Priola; Anne E Ward; Patricia A Goodman; Katherine Olson; Davis M Seelig
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

Review 5.  A critical analysis of disease-associated DNA polymorphisms in the genes of cattle, goat, sheep, and pig.

Authors:  Eveline M Ibeagha-Awemu; Patrick Kgwatalala; Aloysius E Ibeagha; Xin Zhao
Journal:  Mamm Genome       Date:  2008-03-19       Impact factor: 2.957

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.